114 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Mar 24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
9 Nov 23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
4:15pm
is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
10 Aug 23
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
4:11pm
is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) using the binding
8-K
EX-99.1
hihl7ju h4
4 May 23
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
atasnn7 67yr0c
3 Nov 22
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
4:17pm
8-K
EX-99.1
6axsyg
5 May 22
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
7l5su9for 6yptjc4q
10 Mar 22
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
4:15pm
424B5
xkxiqs r01
17 Dec 21
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.1
hpkbvz4wpu2ck8wtd8nx
4 Nov 21
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
4:01pm
8-K
EX-99.1
yuf z6uxl67
5 Aug 21
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
4:00pm
424B5
ofw8gr02ugi2t fiig7h
28 May 21
Prospectus supplement for primary offering
5:23pm